0001209191-23-051480.txt : 20231003
0001209191-23-051480.hdr.sgml : 20231003
20231003162724
ACCESSION NUMBER: 0001209191-23-051480
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231001
FILED AS OF DATE: 20231003
DATE AS OF CHANGE: 20231003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Riley Antony A
CENTRAL INDEX KEY: 0001339375
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38052
FILM NUMBER: 231304139
MAIL ADDRESS:
STREET 1: C/O KRYSTAL BIOTECH, INC.
STREET 2: 2100 WHARTON STREET, SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 94538
FORMER NAME:
FORMER CONFORMED NAME: Riley Anthony A
DATE OF NAME CHANGE: 20050921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Forte Biosciences, Inc.
CENTRAL INDEX KEY: 0001419041
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261243872
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3060 PEGASUS PARK DRIVE
STREET 2: BUILDING 6
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (310) 618-6994
MAIL ADDRESS:
STREET 1: 3060 PEGASUS PARK DRIVE
STREET 2: BUILDING 6
CITY: DALLAS
STATE: TX
ZIP: 75247
FORMER COMPANY:
FORMER CONFORMED NAME: Tocagen Inc
DATE OF NAME CHANGE: 20071120
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-10-01
0
0001419041
Forte Biosciences, Inc.
FBRX
0001339375
Riley Antony A
C/O FORTE BIOSCIENCES, INC.
3060 PEGASUS PARK DR., BLDG 6
DALLAS
TX
75247
0
1
0
0
Chief Financial Officer
0
Common Stock
2023-10-01
4
M
0
9375
0.00
A
186151
D
Common Stock
2023-10-01
4
F
0
3241
0.662
D
182910
D
Restricted Stock Units
2023-10-01
4
M
0
9375
0.00
D
Common Stock
9375
121875
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. Common Stock.
On October 1, 2023, the Reporting Person's RSUs vested. The closing price of Forte Biosciences, Inc.'s Common Stock on September 29, 2023 was the settlement price used to calculate the shares withheld.
Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.
/s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
2023-10-03